Molecules, test kits, test kit components and methods for detecting and measuring different first and second antibodies in a test sample using a single test are provided herein. A method includes the steps of obtaining the test specimen from a subject, transferring the test specimen to a sample receiving portion of an assay of a test kit, and reading the results from the assay. The test kit includes a first molecule comprising a first portion of a protein, wherein the first antibody has a first affinity to bind to the first portion, and a second molecule comprising a second portion of the protein different from the first portion, wherein the second antibody has a second affinity to bind to the second portion.

Disclosed herein include antibodies or fragments thereof having specificity to a sarbecovirus spike protein receptor binding domain. Also provided are compositions, methods, and kits for isolating and using said antibodies or fragments thereof for preventing or treating, for example a coronavirus infection.

The present invention relates to a novel feline paramyxovirus. The paramyxovirus of the present invention is a (−)ssRNA virus and has in one aspect a genome which is complementary to the nucleic acid according to SEQ ID NO:1 or SEQ ID NO:8. The invention further relates to corresponding nucleic acids and polypeptides, antibodies and vaccines. Further, the invention relates to medical uses and diagnostic methods concerning the paramyxovirus of the invention.

Methods for diagnosis of bacterial and viral infections are disclosed. In particular, the invention relates to the use of biomarkers that can determine whether a patient with acute inflammation has a bacterial or viral infection.

The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.

The invention relates to an immunochromatography analysis device which enables simple and rapid diagnosis of dengue virus infection, and an object thereof is to provide an immunochromatography analysis device which can reduce a cross-reaction with a virus belonging to Flaviviridae other than dengue virus and which can specifically detect dengue virus. The invention relates to an immunochromatography analysis device for detecting dengue virus including a sample application part, a labeling substance-holding part, a chromatography medium part having a detection part and an absorption part, wherein the labeling substance-holding part contains a first antibody which recognizes the amino acid sequence of SEQ ID NO: 2 that is present in the whole amino acid sequence of dengue virus NS1 of SEQ ID NO: 1, and the detection part contains a second antibody which recognizes the three-dimensional structure of dengue virus NS1.

The purpose of the present invention is to: provide an agent that effectively suppresses inhibition of antigen-antibody reaction in an immunoassay using a sample containing a body fluid, in particular, a component derived from a biological mucosal membrane, such as saliva; and to suppress false positive and false negative results in the immunoassay. The present invention provides an agent for suppressing inhibition of immune reaction, characterized in that the agent comprises a compound of the following (1) or (2): (1) Sulfonic acid compound of the formula R.sup.1—SO.sub.3H or a salt thereof. (In the formula, R.sup.1 is selected from the group consisting of: a straight-chain C.sub.5-C.sub.30 alkyl group; a straight-chain C.sub.1-C.sub.30 alkyl group substituted with an aryl group having at least one straight-chain C.sub.5-C.sub.30 alkyl group; and an aryl group having at least one straight-chain C.sub.5-C.sub.30 alkyl group. These groups may include a substituent group); and (2) Quaternary ammonium ion of the formula N.sup.+—R.sup.2R.sup.3R.sup.4R.sup.5 or a salt thereof. (In the formula, R.sup.2—R.sup.5 are each independently a straight-chain C.sub.1-C.sub.30 alkyl group, or an aryl group substituted with at least one straight-chain C.sub.5-C.sub.30 alkyl group. These groups may include a substituent group); wherein the agent is capable of suppressing immune reaction inhibitory action caused by a body fluid in an immunoassay sample.

Described are methods for generating human antibodies capable of blocking one or more functions of coronavirus viroporins. The methods can be used to generate therapeutic antibodies to treat or prevent coronavirus infection, including SARS-CoV-2 infection.

Diagnostic devices for performing diagnostic tests are provided, as well as methods that utilize the diagnostic devices, methods for manufacturing the diagnostic devices, and test kits for performing the diagnostic tests. The diagnostic devices include a vial, a rupturable container disposed in an internal cavity of the vial and containing a fluid, and a test and readout device in fluid communication with the internal cavity of the vial. The rupturable container is configured to rupture during a test procedure of the diagnostic test to enable the fluid to flow into the internal cavity of the vial. The rupturable container may include a rupturable ampoule or a frangible seal. The rupturable container may be ruptured by deformation of the vial or by piercing caused by a sharp object in the vial or a sample swab inserted in the vial.

Representative implementations of devices and techniques provide an exemplary system and method for detection and surveillance of an infectious agent, and particularly an agent that is spread through respiratory aerosols. In an embodiment, the system and method include retrieving a face covering that contains oral and/or nasal, and/or skin secretions and/or skin flora on or within a material of the face covering, removing one or more samples of the material of the face covering that contains the secretions from the face covering, and depositing the one or more samples into a predetermined formulation.